ОбзорГрафикНовостиTraderScreen

Soc. Generale Call 170 ABBV 20.12.../  DE000SU2S7U5  /

Frankfurt Zert./SG
11.11.2024  12:08:14 Изменение-0.010 Бид13:01:27 Предложение- Базовый актив Цена исполнения Дата истечения Тип опциона
2.870EUR -0.35% 2.840
Величина цены спроса: 1,100		 -
Величина цены предложения: -		 AbbVie Inc 170.00 USD 20.12.2024 Call
GlobeNewswire 29.08 Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire 28.08 Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
GlobeNewswire 28.08 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 23.08 NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Confere...
GlobeNewswire 19.08 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 15.08 Soleno Therapeutics Announces Updates to its Board of Directors
GlobeNewswire 09.08 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...
GlobeNewswire 08.08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08.08 Aligos Therapeutics Strengthens Board with Two New Independent Directors
GlobeNewswire 08.08 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 08.08 Genmab Updates 2024 Financial Guidance
GlobeNewswire 08.08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 07.08 Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 01.08 Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire 01.08 CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire 01.08 NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
GlobeNewswire 01.08 Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
GlobeNewswire 31.07 Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
GlobeNewswire 31.07 Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR...
GlobeNewswire 30.07 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...
GlobeNewswire 28.07 Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzhei...
GlobeNewswire 25.07 Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Tre...
GlobeNewswire 24.07 Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Sphe...
GlobeNewswire 24.07 Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
GlobeNewswire 24.07 OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial fo...